REMIX THERAPEUTICS, INC.

Section 16 Compliance Policy

To facilitate compliance by officers and directors of Remix Therapeutics, Inc. (the "***Company***") with the reporting requirements of Section 16(a) ("***Section 16***") of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), and the related rules of the U.S. Securities and Exchange Commission (the "***SEC***"), and to prevent inadvertent liability of such persons under the "short-swing" trading rules of Section 16(b), we have implemented this Section 16 Compliance Policy (the "***Policy***").

I. GENERAL INFORMATION REGARDING SECTION 16

A. Background

Section 16 and the related rules of the SEC require officers, directors or holders of 10% or more of the Company's stock, to report all transactions involving Company stock (including options, restricted stock units ("***RSUs***"), warrants and other derivative securities) to the SEC. The requirement extends to transactions by certain of your family members sharing your household, and transactions in which you have an indirect interest (such as transactions by trusts, corporations or partnerships in which you have or share control).

Section 16(b) imposes liability on reporting persons when such transactions occur within a period of less than six months of each other. Under Section 16(b), any combination of a purchase and sale, or a sale and purchase, by a reporting person within a six-month period requires the Company to recover the resulting profit. Under SEC rules, certain transactions, including approved option grants and other transactions under employee benefit plans, are considered "exempt transactions" under Section 16(b) and do not give rise to profit recovery. These exempt transactions in most cases are still required to be reported to the SEC.

B. Filing Responsibilities and Required Forms

Under Section 16, you are personally liable for the failure to file required reports on a timely basis. To assist our officers and directors in meeting required filing deadlines, the Company will prepare and file required Section 16 reports for all approved transactions, unless you have indicated that you prefer to prepare and file your own reports. You will be requested to sign a power of attorney that will give the designated persons at the Company the authority to file on your behalf the following required forms:

- ***Form 3*** must be filed when a person first becomes subject to Section 16. The Form 3 requires the reporting person to list all holdings of Company stock, options, RSUs, warrants, or other derivative securities. The Form 3 must be filed with the SEC within ten calendar days after the reporting person becomes an officer, director or 10% holder.
- ***Form 4*** must be filed whenever there is a change in the beneficial ownership of securities, including acquisitions or dispositions (including dispositions by gift) of Company stock or derivative securities. Changes in a reporting person's

pecuniary interest, even without changes to overall beneficial ownership, will require a Form 4 filing (*e.g.,* transferring shares directly held to a trust for the benefit of the reporting person's minor children). A Form 4 must be filed with the SEC no later than the second business day after a change in beneficial ownership.

- ***Form 5*** may be filed to report certain transactions eligible for deferred reporting and to report failures to file previously due reports. The types of transactions eligible for deferred reporting on Form 5 are extremely limited. Any transaction eligible for deferred reporting may be voluntarily reported on a Form 4 and any missed or late transactions may be reported on a late Form 4 instead of a Form 5. A late transaction, regardless of whether reported on a late Form 4 or timely Form 5, is still considered "delinquent" and must be disclosed in the Company's annual proxy statement (see below). A Form 5, if used, must be filed with the SEC no later than 45 days after the end of the Company's fiscal year.

Officers and directors will be required to provide the Company with an annual written representation confirming:

- compliance with this Policy; and
- if applicable, that no Form 5 is due because all holdings and transactions previously have been reported on Form 3 or Form 4.

Upon request, the Section 16 filing coordinator will review Section 16 reports prepared by 10% stockholders of the Company that are not officers or directors. However, such 10% stockholders will be responsible for preparing and filing their own Section 16 forms.

C. Consequences of Failures to Report

The SEC's rules require the Company to list in its annual proxy statement the names of any Section 16 reporting person who, during the preceding fiscal year, failed to file on a timely basis any of the required reports, in addition to the number of late reports, the number of late transactions and any known failure to file a required form by the reporting person. In addition, the failure to file a required report or untimely filings can have significant consequences, such as the imposition of substantial fines, cease and desist orders and criminal penalties for both the reporting person and the Company.

II. PRE-CLEARANCE AND REPORTING PROCEDURES

A. Designated Filing Coordinators

The Company has designated the Chief Financial Officer (or his or her designees) as the Section 16 filing coordinator to assist reporting persons in obtaining required pre-clearance of all transactions and to prepare all Form 3, 4 and 5 filings.

B. Advance Notification and Pre-Clearance of All Transactions Required

All transactions in Company stock, options, RSUs, warrants, or other derivative securities by officers and directors, or their family members sharing the same household, must be pre-

cleared by the Company's Authorizing Officer, who is the Chief Financial Officer (or his or her designees), in accordance with this Policy and the Company's Insider Trading Compliance Policy. If you or a family member wishes to effect a transaction, you must give notice of the proposed transaction to the Authorizing Officer at least **two** business days prior to the proposed transaction date. You may not execute any transaction in the Company's securities without receiving pre-approval from the Authorizing Officer.

The pre-clearance requirement applies to any change in beneficial ownership of Company equity securities, including purchases, sales, option exercises, transfers, gifts and changes in the form of ownership, and transactions in which you have any indirect interest. No transaction that in any way affects your ownership of Company securities is exempt from this requirement.

You must make arrangements with your family members and fiduciaries, such as trustees of family trusts, to collect all of the information necessary to provide notification to the Company in advance of any transaction in compliance with the pre-clearance requirement.

C. Preparing, Reviewing and Filing Forms 3, 4 and 5

The filing coordinator will oversee the preparation of each Section 16 report. The filing coordinator may require your input whenever there is any acquisition or disposition of equity securities, as well as your assistance in completing the required forms. Due to the requirement to file a Form 4 within two business days of a change in beneficial ownership, it is essential that you respond promptly to the filing coordinator and to provide all information necessary for SEC reporting.

The filing coordinator will file each Section 16 report electronically as required by SEC rules.

D. Power of Attorney

In order to allow Section 16 filings to be filed on a timely basis, officers and directors are requested to sign and return to the filing coordinator the power of attorney attached hereto as Exhibit A. The power of attorney gives the designated individuals the authority to execute and file on your behalf Section 16 reports for all of your transactions and can be beneficial even if you prefer to prepare and file your own Section 16 reports.

E. Your Broker's Obligations

Officers and directors are required to instruct their brokers who handle trades in Company securities to:

- verify with the Company's filing coordinator that the proposed trade was pre-cleared by the Company in advance of entering any trading order for Company stock;
- confirm that the brokerage firm's Rule 144 and other compliance procedures have been followed in connection with all trades; and

- report to the Company's filing coordinator the quantity and price of any trade promptly on the day of execution.

F. Website Posting of Reports

In accordance with SEC rules, the Company's external website will provide a direct hyperlink, accessible by the public generally, to all Section 16 reports filed by our officers, directors and 10% holders.

G. Insider Trading Compliance Policy and Procedures

Before you make any purchase or sale of Company securities, you must review and comply with the Company's Insider Trading Compliance Policy.

H. Transactions Under Rule 10b5-1 Trading Plans

Although transactions effected under a previously pre-approved Rule 10b5-1 trading plan (a "trading plan") or a non-Rule 10b5-1 trading arrangement will not require further pre-clearance at the time of the trade, the transactions (including quantity and execution price) must be reported to the filing coordinator promptly on the day of each trade to permit the filing coordinator to prepare and file a required Form 4. Your broker who implements the trading plan must be instructed to provide such notice to the filing coordinator.

I. Short Sales and Other Prohibited Transactions

Officers and directors are prohibited by Company policy and Section 16(c) from engaging in short sales of the Company's equity securities. Please refer to the Company's Insider Trading Compliance Policy for a description of other prohibited transactions.

J. The Ultimate Responsibility is Yours

While the Company is offering its assistance to its officers and directors to help them comply with the Section 16 rules, you should recognize that it remains your obligation to see that your filings are accurate and made on time, and that you have no Section 16(b) or Rule 10b-5 insider trading liability. You may be held personally liable under the law for missed or late Section 16 reports, notwithstanding that the Company has undertaken to prepare such reports.

Please do not hesitate to contact our Chief Financial Officer or the designated Section 16 filing coordinator if you have any questions about this Policy, about any proposed transaction or about Section 16 reporting requirements generally or in regard to any particular transaction.

* * * * *

Effective November 24, 2026

Exhibit A

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Remix Therapeutics, Inc. (the "***Company***"), the undersigned hereby constitutes and appoints the individuals named on **Schedule A** attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

1. execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), and the rules thereunder, and Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder, and Notices of Proposed Sale of Securities Pursuant to Rule 144 (***"Form 144"***), in accordance with the requirements of Rule 144 under the Securities Act of 1933, as amended (the "***Securities Act***"); and

2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, complete and execute any amendment or amendments thereto, and to timely file such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, as applicable, and any amendment thereto, with the United States Securities and Exchange Commission and any stock exchange or similar authority.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act, or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this ____ day of [Month], 20__.

_____

[Full Legal Name of Reporting Person]

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

Heather Wasserman, Ph.D.
Peter G. Smith, Ph.D.